This phase III study is evaluating the effectiveness of targeted therapy (upifitamab rilsodotin), compared to placebo, in people with recurrent, platinum-sensitive high-grade serous ovarian cancer, including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
This trial is treating patients with platinum-sensitive high-grade serous ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Cooperative Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Commercial Sponsor
Mersana Therapeutics
Summary
Eligible participants will be randomly allocated to either the Experimental Arm or Placebo Comparator Arm. In the Experimental Arm, participants will receive upifitamab rilsodotin once every four weeks via intravenous infusion. In the Placebo Comparator Arm, participants will receive a saline placebo, administered once every four weeks via intravenous infusion.
Recruiting Hospitals Read More